ArissaCarolineYoungMD

PubMed

• 35 citations
  Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programm...
  James R. Patrinely, Arissa Young, Henry Quach, Grant R. Williams, Fei Ye, Run Fan, Leora Horn, Kathryn E. Beckermann, Erin A. Gillaspie, Jeffrey A. Sosman, Debra L. Fr...> ;European Journal of Cancer. 2020 Aug 1
• 58 citations
  Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
  Arissa Young, Henry T. Quach, Haocan Song, Elizabeth J. Davis, Javid Moslehi, Fei Ye, Grant R. Williams, Douglas B. Johnson> ;Journal for Immunotherapy of Cancer. 2020 Jul 1
• 59 citations
  Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
  Carina N. Owen, Alexander N. Shoushtari, Dharmisha Chauhan, D. Palmieri, Belinda Lee, Maartje W. Rohaan, J. Mangana, V. Atkinson, Farzana Y Zaman, Arissa Young, Christ...> ;Annals of Oncology. 2020 Aug 1
• 91 citations
  Hematologic Complications of Immune Checkpoint Inhibitors
  Elizabeth J. Davis, Joe-Elie Salem, Arissa Young, Jennifer R. Green, P. Brent Ferrell, Kristin K. Ancell, Bénédicte Lebrun-Vignes, Javid Moslehi, Douglas B. Johnson> ;The Oncologist. 2019 May 1
• Join now to see all

Lectures

• Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment. 
  2019 ASCO Annual Meeting - 6/1/2019